Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Frequently asked questions
What sector does Bachem Holding AG (BHM) operate in?
Bachem Holding AG belongs to the Materials sector and operates in the Biotechnology industry.
What is Bachem Holding AG (BHM) current stock price?
As of the latest data, Bachem Holding AG stock price is €10.20, with a previous close of €10.20.
What is Bachem Holding AG (BHM) current market capitalization?
Bachem Holding AG market cap is approximately 7.64 billion.
What is Bachem Holding AG (BHM) Earnings Per Share (EPS)?
The trailing EPS is €0.21.
What is Bachem Holding AG (BHM) Price-to-Earnings (P/E) ratio?
Bachem Holding AG current P/E ratio is 48.57.
Does Bachem Holding AG (BHM) pay dividends?
Yes. Bachem Holding AG pays annual dividends with an annualized yield of 1.1% and an estimated annual payout of €0.10 per share.
When is the next ex-dividend date for Bachem Holding AG (BHM)?
The next ex-dividend date is scheduled for May 05, 2027.
What is Bachem Holding AG (BHM) beta (volatility) score?
Bachem Holding AG has a beta of 0.796, indicating lower volatility than the overall market.
